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Abstract. 
 
Thymus development depends on a complex 
series of interactions between thymocytes and the stro-
mal component of the organ. To identify regulated 
genes during this codependent developmental relation-
ship, we have applied an RNA fingerprinting technique 
to the analysis of thymus expansion and maturation 
induced in recombinase-deficient mice injected with 
anti-CD3 antibodies. This approach led us to the identi-
fication of a gene encoding a new member of the immu-
noglobulin superfamily, named epithelial V-like antigen 
(EVA), which is expressed in thymus epithelium and 
strongly downregulated by thymocyte developmental 
progression. This gene is expressed in the thymus and 
in several epithelial structures early in embryogenesis. 
EVA is highly homologous to the myelin protein zero 
and, in thymus-derived epithelial cell lines, is poorly 
soluble in nonionic detergents, strongly suggesting an 
association to the cytoskeleton. Its capacity to mediate 
cell adhesion through a homophilic interaction and its 
selective regulation by T cell maturation might imply 
the participation of EVA in the earliest phases of thy-
mus organogenesis.
 
T
 
hymus 
 
organogenesis depends upon a complex se-
ries of interactions among cells of different embry-
onic origin. The alymphoid epithelial thymic pri-
mordium originates from the third pharyngeal pouch and
requires the inductive effect of mesenchyme for appropri-
ate morphogenesis (Auerbach, 1960). Subsequently, the
advent of hemopoietic precursors at day 10.5 of fetal life
initiates the multiple thymocyte–stroma interactions that
critically settle the architectural and functional organization
of the mature organ (van Ewijk, 1991; Boyd et al., 1993).
The potential role of various cell adhesion molecules in
governing early stages of thymocyte development, as well
as thymic epithelium organization, has been described.
LFA-1/ICAM-1 interactions have been shown to play a
role in thymocyte maturation and proliferation (Fine and
Kruisbeek, 1991). Thy-1 supports adhesion of thymocyte
to thymic epithelial cells through a heterophilic interaction
that can be inhibited by sulfated glycans (Hueber et al.,
1992). The 
 
a
 
6
 
b
 
4 (Wadsworth et al., 1992) and VLA-4
(Sawada et al., 1992) integrins display a developmentally
regulated pattern of expression with the highest level in
thymocyte before TCR rearrangement, suggesting a role
for these molecules in mediating adhesion of early thy-
mocyte to stroma. Extracellular matrix proteins have been
detected in the thymus; it has been shown that early thy-
mocytes adhere to thymus epithelium through fibronectin
expressed by the stromal cell and that blockade of this in-
teraction has an impact on T cell maturation (Utsumi et al.,
1991). Additionally, merosin–thymocyte interaction has
been suggested to play a role in T cell development
(Chang et al., 1993). Recently, homophilic E-cadherin in-
teractions have been shown to be critically involved in the
generation of a functional thymic environment and in cel-
lular interactions occurring in the early phases of T cell de-
velopment (Muller et al., 1997).
Maturation of 
 
ab
 
 T cells is characterized by the progres-
sion of double negative (DN)
 
1
 
 precursors expressing nei-
ther CD4 nor CD8, to a double positive (DP) CD4
 
1
 
8
 
1
 
stage after low-level CD8 expression. As defined by inter-
leukin-2 (IL-2) receptor (CD25) and CD44 expression, the
DN stage can be ordered in the following developmental
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1.
 
 Abbreviations used in this paper
 
: aa, amino acid; DN, double negative;
DP, double positive; endo-H, endo-
 
b
 
-
 
N
 
-acetyl-glucosaminidase H; EST,
expressed sequence tag; 
 
Eva
 
, epithelial V-like antigen; KRH, Krebs–
Ringer–Hepes; p.c., post coitum; Po, myelin protein zero; RAG-2
 
2
 
/
 
2
 
, re-
combinase–activating-2 gene deficient; RPA, RNase protection assay; RT,
reverse transcriptase.
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sequence of phenotypes: DN CD44
 
1
 
25
 
2
 
 
 
. 
 
DN CD44
 
1
 
25
 
1
 
. 
 
DN CD44
 
2
 
25
 
1
 
 (Godfrey and Zlotnik, 1993). The at-
tainment of DP stage is defined 
 
b
 
 selection, because it is
mainly controlled by TCR
 
b
 
 gene rearrangement and ex-
pression in association with pre-TCR-
 
a
 
 (von Boehmer and
Fehling, 1997). Cells that have succeeded in 
 
b
 
 selection ex-
pand and undergo a further recombination event allowing
TCR-
 
a
 
 rearrangements to occur (Petrie et al., 1993), fol-
lowed by major histocompatibility complex–driven clono-
typic 
 
ab
 
 selection (von Boehmer, 1994). Recombinase–
activating-2 gene deficient (RAG-2
 
2
 
/
 
2
 
) mice, in which
TCR-
 
b
 
 gene cannot rearrange, display a block at the
CD44
 
2
 
CD25
 
1
 
 stage (Shinkai et al., 1992). A scarcely pop-
ulated cortex is apparent and there is absence of the med-
ullary compartment (Holländer et al., 1995), consistent
with the observed requirement for a functionally “mature”
TCR–CD3 complex for the development of the medulla
(Negishi et al., 1995). In vivo
 
 
 
treatment of RAG-2
 
2
 
/
 
2
 
 mice
with anti-CD3
 
e 
 
mAb induces transition of DN into DP
thymocytes with cell proliferation, cell size reduction, and
other phenotypic modifications characteristic of this tran-
sition (Jacobs et al., 1994; Shinkai and Alt, 1994). In this
respect, the RAG-deficient thymus offers a unique oppor-
tunity to obtain the earliest lymphoid precursors uncon-
taminated with later-stage cells, and an organ phenotypi-
cally arrested at 14 or 15 d of embryonic life that can be
induced to expand and differentiate.
To identify genes whose expression is selectively regu-
lated during thymus development, we applied a PCR-based
differential screening approach (RNA fingerprinting)
(Malgaretti et al., 1997), comparing thymus RNAs extracted
from untreated RAG-2
 
2
 
/
 
2
 
 mice and from the same mu-
tants treated in vivo with anti-CD3
 
e
 
 antibodies. Among
other genes displaying differential expression identified in
this way, we have isolated a new member of the immuno-
globulin gene superfamily. The gene, named epithelial
V-like antigen (
 
Eva
 
), encodes a putative transmembrane
type 1 glycoprotein, bearing an immunoglobulin V-type
domain. The gene is expressed at high levels in the thymic
epithelium of RAG-2
 
2
 
/
 
2
 
 mice and is almost completely
downregulated by in vivo treatment with anti-CD3
 
e
 
mAbs. The gene is expressed in thymus-derived epithelial
cell lines and in various epithelia in development and
adulthood. Here, we present the cloning, sequence, and
initial genetic, biochemical, and functional characteriza-
tion of this new protein of potential relevance as homo-
typic adhesion molecule in development, specifically in the
early stages of thymus organogenesis.
 
Materials and Methods
 
General Procedures 
 
Standard molecular techniques, including nucleic acid purification, restric-
tion analysis, gel electrophoresis, cloning, subcloning, dideoxy-sequenc-
ing, probe radiolabeling, Northern and Southern analysis, and library
screening were performed according to established protocols (Sambrook
et al., 1989).
 
Animals 
 
4-wk-old C57BL/6 and CD-1 mice were purchased from Charles River
Laboratories (Calco, Italy) and RAG-2
 
2
 
/
 
2
 
mice were purchased from
Bomholtgard (Ry, Denmark). All mice were bred and maintained in a
 
specific pathogen-free facility at DIBIT-HSR Scientific Institute. RAG-2
 
2
 
/
 
2
 
mice were i.v. injected with 50 
 
m
 
g of anti-CD3
 
e
 
 mAb.
 
Cell Lines, Antibodies, and Primers 
 
The following cell lines were used in this study: thymus epithelium–
derived A89A, A2T (Hiai et al., 1985), TEC (Glimcher et al., 1983), MTE
(Lepesant et al., 1990), 24B6 (Yanagihara et al., 1981),
 
 
 
and TNC.R3.1
(Nishimura et al., 1990); thymocyte-derived BW5147 (Hyman and Stall-
ings, 1974), M15T, and M14T (Primi et al., 1988); thymic fibroblast 1D4
(Izon et al., 1994); NIH3T3 (CRL-1658; American Type Culture Collec-
tion, Rockville, MD); bone marrow stroma–derived BMS2 (Pietrangeli et
al., 1988), M210 (provided by A. Aiuti, San Raffaele Scientific Institute,
Milan, Italy), and MS-5 (Itoh et al., 1989);
 
 
 
multipotent hemopoietic stem
cell FDCP mix (Spooncer et al., 1986);
 
 
 
fetal skin–derived dendritic cell
FSDC (Girolomoni et al., 1995); macrophage cell line MT2 (Lutz et al.,
1994); mature T cell line M15S (Primi et al., 1988); monkey COS7 fibro-
blasts (Gluzman, 1981); and CHO cells (provided by R. Sitia, San Raffaele
Scientific Institute). All cell lines were maintained in DME (GIBCO
BRL, Gaithersburg, MD) supplemented with 2 mM 
 
l
 
-glutamine, 1 mM
sodium pyruvate, 5 
 
3 
 
10
 
2
 
5
 
 M 
 
b
 
-mercaptoethanol, 50 U/ml streptomycin,
and 10% FCS.
The following mAbs were used in this study: 145-2C11 (anti-CD3
 
e
 
)
(Leo et al., 1987);
 
 
 
H129.19 (anti-CD4), 53-6.7 (anti-CD8), AMT-13 (anti-
CD25), and AC-40 (anti-actin) (Sigma Chemical Co., St. Louis, MO);
9.3.4.HL.2 (anti-murine CD45) (TIB-122; American Type Culture Collec-
tion); G7 (anti-CD90/Thy-1), RA3-6B2 (anti-CD45R/B220) (PharMin-
gen, San Diego, CA); F4/80 (anti-macrophage) (Austyn and Gordon,
1981); 9E10 (anti-myc, CRL-1279; American Type Culture Collection);
327 (anti-v-src) (Oncogene Science, Inc., Manhasset, NY). Rabbit antise-
rum specific for EVA was obtained by immunizing rabbit 833 with a pep-
tide corresponding to the 21 NH
 
2
 
-terminal residues of the predicted ma-
ture protein. The immune serum was affinity purified on EAH Sepharose
48 (Pharmacia Biotech, Inc., Piscataway, NJ) coupled to the relevant pep-
tide. Rabbit complement was purchased from Cedarlane Labs, Ltd.
(Hornby, Ontario, Canada). 
The following primers were used in this study: DR122 5
 
9
 
-GGGACG-
TCTACG; Eva forward G1.F 5
 
9
 
-CACGACTGGTTGGCTCCGCT, G1.RT
5
 
9
 
-GGGTGGTCTGGGACGGAAAC; Eva reverse G1.A5
 
 
 
5
 
9
 
-GTGTG-
CACAACGCTGAGCCGG, G1.T3ON 5
 
9
 
-GGGGTGCTGATGGTGT-
CCTC; 
 
b
 
 actin forward 5
 
9
 
-TGACGGGGTCACCCACACTGTGCCC-
ATCTA, 
 
b
 
 actin reverse 5
 
9
 
-CTAGAAGCATTTGCGGTGGACGATG-
GAGG.
 
Gene Isolation and Sequence Analysis 
 
PCR-based differential screening (RNA fingerprinting) (Welsh et al.,
1995)
 
 
 
was conducted as previously described (Corradi et al., 1996; Malga-
retti et al., 1997)
 
 
 
to compare mRNAs of thymi from untreated C57BL/6,
RAG-2
 
2
 
/
 
2 
 
mice and RAG-2
 
2
 
/
 
2 
 
mice i.v. injected with 50 
 
m
 
g of 145-2C11
mAb. In the case of treated animals, thymi were dissected 2, 6, and 48 h af-
ter antibody injection. DR122 was the arbitrary 12 mer primer used. Thy-
mus RNA extracted from adult RAG-2
 
2
 
/
 
2
 
mice was used to construct a
cDNA library cloned into Lambda Zap II (Stratagene, La Jolla, CA). The
cDNA isolated by RNA display (G1) was used as a probe to screen library
filters containing 10
 
6
 
 plaques. Four positive clones were sequenced auto-
matically through a sequencer (model 373; Applied Biosystems, Inc., Fos-
ter City, CA) and manually by dideoxy sequencing (Sequenase 2.0, USB,
Cleveland, Ohio). Sequences were analyzed through the MacVector soft-
ware (Oxford Molecular Group) and a contig was assembled through the
Sequencher software (DNA Codes). The putative transcription initiation
was mapped through the RACE protocol (Frohman et al., 1989). The re-
sulting nucleotide and peptide sequences were aligned to databases of ex-
isting sequences through the BLAST network server (Altschul et al.,
1990) and through a local Genetics Computer Group (GCG, Madison,
WI) package (Devereux et al., 1984). Sequence searches were run against
the GenBank, Swissprot, and dbEST databases.
 
Genetic Mapping
 
Genetic mapping was achieved using a ([C57BL/6j 
 
3 
 
SPRET/Ei]F
 
1 
 
3
 
SPRET/Ei) backcross (BSS) generated and distributed by The Jackson
Laboratory (Bar Harbor, ME) (Rowe et al., 1994). A 596-bp G1.F/G1.A5
PCR fragment corresponding to the 5
 
9
 
 of the 
 
Eva
 
 cDNA was used as a probe
to identify a Taq1 restriction fragment length polymorphism (RFLP) by
Southern hybridization. Its segregation was followed on 96 DNAs, corre- 
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sponding to the parentals and 94 N
 
2
 
 progeny, and then linkage analysis was
performed with the MapManager 2.6 program (Manly and Elliott, 1991).
The human 
 
Eva
 
 orthologue was mapped in the human genome by
Southern blot analysis on nine different YAC clones from the CEPH li-
brary (Albertsen et al., 1990) (735-C-9, 742-F-9, 785-C-6, 822-G-8, 828-G-11,
886-D-9, 901-A-11, 936-D-9, and 969-D-7). DNAs were digested with
EcoRI and then hybridized with a radiolabeled 
 
Eva
 
 probe spanning the
complete coding region. YAC clones were chosen based on sinteny with
the mouse mapping position.
 
RNase Protection Assay 
 
An antisense riboprobe was generated by in vitro transcription of the G1
fragment subcloned into pBluescript with T3 RNA polymerase and incor-
poration of [
 
a
 
32
 
P]UTP (800 Ci/mmol) (Promega Corp., Madison, WI). 50 
 
m
 
g
RNA from each of different adult mouse tissues were hybridized, treated,
and then PAGE separated as described (Ausubel et al., 1995). A densito-
meter and the ImageQuant software (both from Molecular Dynamics,
Inc., Sunnyvale, CA) were used for quantitative analysis of autoradiographs.
Value normalization was achieved through a mouse 
 
b
 
-actin riboprobe.
 
Reverse Transcriptase-PCR
 
B cells were isolated from a C57BL/6 spleen. After organ disruption, T
cells were eliminated by complement-mediated cell lysis after incubation
with anti-CD4, anti-CD8, and anti-Thy-1 mAbs (Coligan, et al., 1994).
Then, B cells were positively selected with anti-B220 magnetic microbeads
according to miniMACS cell sorting protocol (Miltenyi Biotec, Sunnyvale,
CA). Mature T lymphocytes were positively selected with anti-Thy 1.2
magnetic microbeads from C57BL/6 mesenteric lymphonodes after B-cell
depletion with anti-B220 magnetic microbeads. DN thymocytes were iso-
lated from C57BL/6 thymi by positive selection with anti-CD25 mAb and
goat anti–rat IgG magnetic microbeads. DP, single positive (SP) thy-
mocytes, and macrophages were previously eliminated by complement-
mediated lysis after incubation with anti-CD4, anti-CD8, and anti-mac-
rophage
 
 
 
mAbs. Macrophages were isolated from the peritoneal cavity
(Coligan et al., 1994). Freshly drawn dendritic cells were obtained as de-
scribed (provided by F. Galbiati, Hoffmann-La Roche, Milan, Italy)
(Guery et al., 1996). Embryos at different days of gestation were sepa-
rated from extraembryonic tissues under a dissection microscope. RNAs
were isolated as described (Chomczynski and Sacchi, 1987). cDNA was
generated from 1 
 
m
 
g of RNA by using murine Moloney leukemia virus re-
verse transcriptase (RT) and oligo-dT (16 mer). G1-RT and G1-T3ON
primer pair was used. The size of the amplified fragment on cDNA is 412
bp, whereas no amplified fragment is obtained from genomic DNA.
 
In Situ Hybridization
 
Mouse embryos of outbred CD-1 strain and thymi from RAG-2
 
2
 
/
 
2 
 
mice
were embedded in paraffin, sectioned at 6 
 
m
 
m, and then treated for in situ
hybridization as described previously (Teesalu et al., 1996). The putative
complete 
 
Eva
 
 coding sequence, subcloned into pBluescript II SK (Strat-
agene), termed Eva.cds was used to generate sense and antisense 
 
35
 
S-labeled
probes. After hybridization and washes, slides were dipped into Kodak
NTB2 emulsion (Eastman-Kodak, Rochester, NY), exposed at 4
 
8
 
C for 1–3 wk
and, after standard development, stained with toluidine blue and mounted
in DPX mountant (BDH Chemicals Ltd., Dagenham, Essex, UK). Slides
were observed and photographs were taken using an Axiophot microscope
(Carl Zeiss, Inc., Thornwood, NY).
 
In Vitro Translation and Transfectants 
 
The Eva.cds construct was used for in vitro transcription and translation
experiments in the presence of [
 
35
 
S]methionine, with or without microso-
mal membranes, as specified by the manufacturer (Promega Corp.). In
some experiments, 10 
 
m
 
l of translation mix were treated with the enzyme
endo-
 
b
 
-
 
N
 
-acetyl-glucosaminidase H (endo-H) (Boehringer Mannheim
Corp., Indianapolis, IN) as described (Ceriotti et al., 1995). Samples were
analyzed by SDS-PAGE under reducing conditions and the resolved
products were detected by fluorography.
A construct encoding the putative complete EVA protein tagged at
the COOH terminus with a c-myc–derived epitope (Wong and Cleveland,
1990) was subcloned into pcDNA3 (Invitrogen, Carlsbad, CA) and intro-
duced in monkey COS7 fibroblasts by DEAE-dextran–mediated transfection.
48 h after transfection, cells were trypsinized, plated on poly-
 
l
 
-lysine–coated
glass coverslips (10
 
5
 
 cells), fixed with 3% paraformaldehyde, permeabi-
lized with 0.15% Triton X-100 in PBS for 5 min, and immunolabeled
with 9E10 anti-myc mAb followed by FITC-conjugated F(ab
 
9
 
)2 fragments
of goat anti–mouse IgG (Protos Immunoresearch, San Francisco, CA).
Stable transfectants were obtained by introducing the same Eva.myc con-
struct in CHO cells with the calcium-phosphate precipitation protocol and
maintaining the cells in medium supplemented with G418 (600 
 
m
 
g/ml).
 
Biochemical Analysis
 
A89A and TNC.R3.1 cells were washed three times with cold PBS, resus-
pended in ice-cold nuclease buffer (50 
 
m
 
g/ml Staphylococcal nuclease,
2mM CaCl
 
2
 
, 20 mM Tris-HCl, pH 8.8) for detachment with a cell scraper.
The same nuclease buffer solution was used to harvest multiple plates to
reach the final concentration of 50 
 
3 
 
10
 
6
 
 cells/ml. The following antipro-
teases were added: 100 mM PMSF, 10 
 
m
 
g/ml leupeptin, and 10 
 
m
 
g/ml
aprotinin; then 0.3% SDS and 10% 
 
b
 
-mercaptoethanol were added and
mixed on ice. Finally, 100 
 
m
 
g/ml DNase I and 50 
 
m
 
g/ml RNase A were
added. Lysates were homogenized by passage through a 23-gauge syringe
and were centrifuged in a microfuge for 10 min. COS7 and CHO transfec-
tants were lysed in Triton X-100 lysis buffer (1% Triton X-100, 5 mM
EDTA, 1 mM iodoacetamide, 1 mg/ml BSA, 10 mM Tris, pH 8.8, 0.15 M
NaCl). Samples were subjected to SDS-PAGE under reducing conditions
followed by transfer to nitrocellulose membranes and immunoblotted
with 9E10 mAb and anti-EVA rabbit serum. Bound antibodies were re-
vealed by peroxidase-conjugated goat anti–mouse (Dako Corp., Carpinte-
ria, CA) or –rabbit (Sigma Chemical Co.) Ig sera, using the enhanced
chemiluminescence detection system (Amersham Pharmacia Biotech,
Inc., Piscataway, NJ).
 
Cell Fractionation
 
A89A and TNC.R3.1 cells were detached by incubation at 37
 
8
 
C for 10 min
in 1 mM PBS-EDTA (10 ml for 50 ml of culture). After two washes in
ice-cold PBS, cells were resuspended at 5 
 
3 
 
10
 
6
 
/300 
 
m
 
l in hypotonic buffer
(20 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM MgCl
 
2
 
, 0.5 mM DTT, and
protease inhibitors) and incubated for 10 min on ice. Cells were then dis-
rupted by homogenization on ice with a Dounce homogenizer (30 strokes
at low speed and 10 strokes at maximum speed). Salt concentration was
adjusted to 150 mM NaCl and intact cells, nuclei, and cytoskeleton were
pelleted by centrifugation at 5,000 rpm for 5 min in a microfuge (Eppen-
dorf Scientific Inc., Hamburg, Germany) at 4
 
8
 
C. After two washes in hy-
potonic buffer, the pellet (P1) was resuspended in Laemmli sample buffer.
The low-speed supernatant was centrifuged at 100,000 
 
g
 
 for 30 min and
the resulting pellet (P100) was considered the membrane fraction,
whereas the supernatant (S100) was considered the soluble proteins frac-
tion. Equivalent amounts of all samples were resolved by SDS-PAGE in a
5–15% gradient gel and then immunoblotted with the indicated antibodies.
 
Cell Aggregation Assay
 
CHO cells, both pcDNA3- and Eva.myc-transfected, were detached by in-
cubation at 37
 
8
 
C for 10 min in 1mM PBS-EDTA. After two washes in low-Ca
Krebs–Ringer–Hepes (KRH) buffer (125 mM NaCl, 5 mM KCl, 1 mM
MgSO4, 1 mM KH2PO4, 0.1 mM CaCl2, 33 mM glucose, 25 mM Hepes),
cells were resuspended in low-Ca KRH-2% FCS (predialyzed against
low-Ca KRH) to a final concentration of 2 3 106 cells/ml by three pas-
sages through an 18-gauge syringe. Single-cell suspensions were incubated
in 2.5-ml polypropylene tubes with gentle rotation for 60 min at 378C.
Cells were finally plated on glass coverslips, treated, and then immunola-
beled as described above. In similar experiments, cells were labeled with
different fluorescent lipophilic dyes (Sigma Chemical Co.) before aggre-
gation assay (Litvinov et al., 1994): either PKH2 (green fluorochrome) for
Eva.myc-transfectants, or PKH26 (red fluorochrome) for vector-trans-
fected CHO cells, were used. Aggregation index was calculated as D 5
(N0 2 Nt)/N0, where N0 is the initial number of particles corresponding to
the total number of cells, and Nt is the number of remaining particles at
the incubation time point t (Shimoyama et al., 1992).
Results
Identification and Cloning of Eva
To identify regulated genes during thymus development,
we applied a modified RNA fingerprinting protocol (Mal-The Journal of Cell Biology, Volume 141, 1998 1064
garetti et al., 1997) to thymi from RAG-22/2 mice at differ-
ent intervals after the injection of anti-CD3e mAb (2, 6,
and 48 h). We identified a 436-nucleotide band (G1) that
was selectively amplified in the thymus cDNA from un-
treated RAG-22/2 mice. The same band was also detected
in cDNA from RAG-22/2 mice 2 and 6 h after treatment,
but was almost absent at 48 h (Fig. 1). The band was gel-
excised, reamplified, and then cloned into pBluescript II
SK. Clones were screened as described (Consalez et al.,
1996) and the plasmid G1.A2 was sequenced manually. A
database search was run with BLASTN and BLASTX, us-
ing the GCG interface (Devereux et al., 1984). One mouse
expressed sequence tag (EST) sequence (GenBank/EMBL/
DDBJ accession number AA288427), and several human
ESTs (AA336903, H77296, W61215, H48606, AA088807,
and N70439) displayed clear similarities to the G1 cDNA
(from 99 to 84% identity). cDNA G1.A2 showed an open
reading frame of 286 nucleotides, preceded by an in-frame
stop codon. G1.A2 was used as a probe to screen a cus-
tom-made RAG-22/2 thymus cDNA library. Sequence
analysis and assembly of four positive clones revealed a
645-bp open reading frame encoding a deduced 215-amino
acid (aa)-long sequence. Analysis of the predicted aa se-
quence with PROSITE, BLOCKS, and TMAP indicates
that G1 encodes a type 1 transmembrane glycoprotein
(Fig. 2 A), with a presumptive cleavable 20-aa-long signal
peptide and a putative 25-aa-long transmembrane region
(residues 151–175). Sequence comparison and alignments
done with the PILEUP program showed a putative extra-
cellular region containing a V-like domain: two cysteines
(positions 47 and 123), corresponding to the invariant cys-
teines that form the intrachain disulfide bond in the Ig do-
main, are located 76 residues apart. The tryptophan at po-
sition 63, as well as other residues, such as glycine 40,
arginine 90, leucine 109, and tyrosine 121 are typical fea-
tures of V domains (Carayannopoulos and Capra, 1993).
In addition, two potential glycosylation sites and a puta-
tive serine phosphorylation site were observed (Fig. 2, A
and B). Based on database search results, we also se-
quenced the human cDNA clone containing H48606
EST, derived from a fetal liver/spleen expression library
(I.M.A.G.E. clone N8202065). The human-derived se-
quence revealed the same features of G1 (Fig. 2 A), with
an identity of 79 and 85% at the nucleotide and aa level,
respectively. Moreover, database search results and se-
quence alignment revealed 33% identity and 45% homol-
ogy with the myelin protein zero (Po), the predominant
myelin protein in the peripheral nervous system (Fig. 2 C)
(Lemke and Axel, 1985). The G1 nucleotide sequence did
not match any known gene and protein (GenBank, EMBL,
Swissprot, PIR), and thus represents a new gene, encoding
a likely new member of the immunoglobulin superfamily.
Based on the sequence and expression data (see below)
we named this new gene Eva, for epithelial V-like antigen.
Chromosomal Localization of the Mouse and Human 
Eva Genes 
A TaqI polymorphism was used to type the segregation of
Eva alleles in the 94 individual N2 progeny of the BSS
Figure 1. RNA fingerprinting experiment comparing cDNAs of
thymi from C57BL/6, untreated RAG-22/2 mice and RAG-22/2
mice at different times (2, 6, and 48 h) after i.v. injection of anti-
CD3e mAb. RNA fingerprinting RT-PCR reactions were con-
ducted in duplicate at each stage examined. Arrowhead; band
corresponding to the Eva transcript.
Figure 2.( A ) Alignment of the aa sequences en-
coded by human and murine Eva cDNAs. Left,
aa numbering. The predicted leader (signal pep-
tide) and transmembrane sequences are labeled
together with the following features: dark-
shaded boxes, potential N-linked glycosylation
sites; light-shaded boxes, cysteine residues (47
and 123) found in conserved positions within the
V-type domain; bold residues, potential protein
casein kinase 2 phosphorylation site. These se-
quence data are available under GenBank/
EMBL/DDBJ accession numbers AF030455 (for
human Eva) and AF030454 (for mouse Eva). (B)
Model of EVA protein according to prediction
results. \, N-linked glycosylation sites; P, putative
protein CK2 phosphorylation site in the cyto-
plasmic tail. (C) Sequence alignment of mouse
EVA and myelin Po proteins. Boxed residues
are identical in the two proteins (33%); homolo-
gous residues are shaded (45%).Guttinger et al. Regulated Expression and Potential Role of EVA 1065
backcross by RFLP analysis. 90 out of 94 progeny were
successfully typed. Linkage analysis unequivocally local-
ized Eva to mouse chromosome (chr.) 9, 2.25 cM distal to
Xmv16 (LOD score 22.6), and 1.12 cM proximal to
Cyp1a2 (logarithm of the odds [LOD] score 24.4). The
data are summarized in Fig. 3.
The human Eva orthologue was localized to chr. 11q24
by Southern blot analysis of YAC clones from the CEPH
library. The YACs had been identified based on data bank
information; in fact, some of the human ESTs homologous
to  Eva (namely H77296 and H48606, 84% identical to
Eva) had been localized on chromosome 11q, between
D11S1341 and D11S924, to the human genomic region
syntenic to the mouse map position. DNA from nine YAC
clones spanning that region were analyzed by Southern
hybridization with a probe containing the complete Eva
coding region. Of all YACs tested, Eva hybridizes YACs
822-G-8 and 828-G-11. YAC 828-G-11 has been mapped
cytogenetically to 11q24 (Rocchi, M., see data available
at http://bioserver.uniba.it/fish/rocchi/webbari/2_YAC/800-
899/828G11.html).
Regulated Expression of the Eva Gene in
RAG-22/2 Thymus
To confirm the expression data obtained by RNA finger-
printing, we performed Northern analysis on total RNAs
extracted from thymi of C57BL/6 and RAG-22/2 mice at
different intervals after the injection of anti-CD3e mAb (2, 6,
and 48 h). Hybridization was carried out with radiolabeled
G1.A2 cDNA. As shown in Fig. 4 A, a 3.4-kb transcript in
untreated RAG-22/2 thymi as well as in RAG-22/2 thymi at
2 and 6 h after injection was revealed. As predicted from
the RNA fingerprinting pattern, no expression was detect-
able in wild-type and in RAG-22/2 thymi 48 h after treat-
ment. RNase protection assay (RPA) performed on the same
samples (Fig. 4 B) revealed that Eva was also detectable in
wild-type and RAG-22/2 thymi 48 h after treatment upon
a long gel exposure. Densitometric analysis after normal-
ization with actin showed that Eva expression levels decrease
at least 20-fold in RAG-22/2 thymi 48 h after the treatment
(data not shown). Furthermore, to confirm downregulation
of the Eva transcript in this experimental model, we per-
formed radioactive mRNA in situ hybridization experiments.
The RAG-22/2 thymus displayed a strong and uniform sig-
nal for the Eva transcript (Figs. 5 and 6), reminiscent of
the embryonic thymus pattern (see below), whereas RAG-
22/2 thymus 48 h after injection failed to show any signal
above background (Fig. 5, C and D); an analogous result
was also obtained with wild-type thymus (data not shown).
Eva Distribution in Mouse Tissues and Cell Lines
Total RNA purified from adult mouse organs was used in
Figure 3. Mapping of Eva in the mouse genome. Top: haplotype
and linkage analysis of Eva and flanking loci on mouse chromo-
some 9 through the analysis of the BSS backcross (The Jackson
Laboratory). Empty squares, Mus spretus allele; solid squares,
C57BL/6J allele; stippled squares, genotype not determined.
Numbers to the right, between rows, indicate recombination frac-
tions 6 standard error, and LOD scores. Columns represent dif-
ferent haplotypes observed on chromosome 9. Numbers below
columns define the number of individuals sharing each haplo-
type. Bottom: position of Eva on chromosome 9 with respect to
nearby markers independently mapped by others on the BSS
backcross. Numbers on the left represent approximate genetic
distances (cM) from the most centromeric chromosome 9 marker
in this cross. Chromosomal locations of three syntenic human
genes, including EVA, are also indicated.
Figure 4.( A ) Eva mRNA expression in wild-type and RAG-22/2
thymi. Northern analysis on total RNA isolated from thymi of
C57BL/6, untreated RAG-22/2 mice and RAG-22/2 mice at dif-
ferent times (2, 6, and 48 h) after anti-CD3e mAb injection. After
hybridization with a labeled cDNA specific for Eva, the filter was
stripped and again hybridized with a labeled b-actin probe. The
apparent size of the transcript is indicated. (B) Eva mRNA ex-
pression in various adult mouse tissues. RNase protection assay
with a 437-bp Eva-specific antisense riboprobe on seven adult
mouse tissues and thymi of C57BL/6, untreated RAG-22/2 mice,
and RAG-22/2 mice i.v. injected with anti-CD3e mAb. Results
obtained with mouse b-actin riboprobe are also shown. (C) Eva
mRNA expression in different thymic epithelial cell lines. RT-
PCR on mRNA of four thymic epithelial cell lines (A2T, A89A,
TEC, and TNC.R3.1). Gene expression on RAG-22/2 thymus was
used as control. cDNA-amplified fragment is 412-bp long.The Journal of Cell Biology, Volume 141, 1998 1066
RPA to characterize the tissue distribution of the Eva
transcript. As shown in Fig. 4 B, high expression levels of
Eva were observed in the liver and gut, lower levels in the
kidney, and very low ones in the lung and brain. No ex-
pression was observed by RPA in the spleen and heart.
High levels of expression were also found in gut and liver
from RAG-22/2 mice (data not shown). Eva expression
was also detected in the skin and testis by RT-PCR (Table
I). Furthermore, we could detect the Eva transcript in
wild-type fetal thymus and liver at day 13.5 post coitum
(p.c.) and in whole embryos at the early primitive streak
stage (day 7.5 p.c.) (Table I).
To assess the cellular specificity of the Eva transcript,
we performed RT-PCR on purified cell populations. Table
I summarizes the results that define the non-T cell nature
of the transcript. In fact, Eva was neither expressed in pu-
rified DN/CD251 thymocytes that constitute the most
abundant cell population in RAG-22/2 thymus, nor in ma-
ture T cells. Similarly, no expression was observed in ma-
ture B lymphocytes, macrophages, dendritic cells, and
bone marrow. To define the histological identity of Eva-
expressing cells, we tested various cell lines by RT-PCR.
No expression was observed either in MS-5, M210, and
BMS2 cells (bone marrow stroma-derived), or in FDCP
mix (representing multipotent hemopoietic precursor).
Negative results on M15S, NIH3T3, MT2, and FSDC con-
firmed that Eva is not expressed in T lymphocytes, fibro-
blasts, macrophages, and dendritic cells. Interestingly, Eva
Figure 5. mRNA in situ
hybridization of RAG-22/2
thymi. Eva expression by
RAG-22/2thymi from un-
treated mice (A and B) and
treated animals at 48 h after
injection of antibody (C and
D). Bright-field views (A and
C) and dark-field images (B
and D). Note strong, homo-
geneous labeling of RAG-22/2
thymus, and absence of Eva
expression in the thymus
from injected mice.
Figure 6. Eva mRNA in situ
hybridization at 13.5 d p.c. (A
and B) and 14.5 d p.c. (C and
D) embryonic tissue sections.
Bright-field images (A and
C) and dark-field micropho-
tographs (B and D). (A and
B) High levels of Eva tran-
scripts are found in the
emerging thymus (A, ar-
rows). Specific labeling can
also be seen in epithelia lin-
ing the respiratory and gas-
trointestinal tracts: trachea,
esophagus, gut and alveoli
are indicated by arrowheads.
(C and D) Note labeling of
surface ectoderm and sub-
mandibulary salivary glands
(arrowheads). Bars: (A and B),
165 mm; (C and D), 330 mm.Guttinger et al. Regulated Expression and Potential Role of EVA 1067
transcript is clearly expressed in four (TEC, MTE, 24B6,
and TNC.R3.1) out of six thymic epithelial cell lines (Ta-
ble I and Fig. 4 C).
Localization of Eva Transcript during
Mouse Development 
We used radioactive in situ hybridization to localize Eva
transcripts in mouse 8.5- and 9.5-d p.c. embryo implanta-
tion sites and in 12.5–16.5 d p.c. embryos. At 8.5-d p.c.,
abundant Eva expression was found in the extraembryonic
ectoplacental cone and giant trophoblasts (Teeslau, T.,
manuscript in preparation), which are trophoectoderm-
derived cells important for embryo implantation and pla-
centa formation. In mouse embryos, Eva expression was
found in a number of epithelial structures: surface ecto-
derm, and epithelia lining gastrointestinal and respiratory
tracts as well as salivary glands (Fig. 6). At 13.5-d p.c., a
prominent signal is evident in the developing thymus (Fig.
6,  A  and  B), and persists through the later embryonic
stages analyzed (data not shown).
Characterization of the EVA Protein
To validate sequence analysis data and assess the size of
the peptide translated from Eva cDNA corresponding to
the open reading frame, we performed in vitro transcrip-
tion and translation, the latter in the presence or absence
of microsomal membranes (Fig. 7 A). The translation
product was subjected to SDS-PAGE analysis and two
peptide bands, the more abundant migrating with a molec-
ular mass of 32 kD and a weaker one of 30 kD, were ob-
tained only in the presence of microsomal membranes
(Fig. 7 A, lane 6). Lack of protein product in Fig. 7 A, lane
5, at this exposure time, represented the transitional arrest
by the excess of signal recognition particles described for
secretory proteins in reticulocyte lysate system (Wolin and
Walter, 1989). This observation suggested that EVA is a
membrane-bound protein. The observed protein size was
greater than the predicted one (24.5 kD), suggesting post-
translational modifications of the peptide product. Consis-
tently, treatment of the translated polypeptide with endo-H
enzyme resulted in the appearance of two additional smaller
bands of 30 and 24 kD, respectively, likely to be deglycosy-
lation products (Fig. 7 A, lane 8).
To further substantiate EVA expression at the cell sur-
face, a construct encoding EVA in frame with a COOH-
terminal myc epitope tag (Eva.myc) was generated and
transfected into cultured COS cells. A cellular immunoflu-
orescence experiment run on permeabilized transfectants
revealed that EVA is clearly present at the cell plasma
membrane (Fig. 7 B).
An anti-myc immunoblot on Triton X-100 lysates of
CHO cells transfected with the Eva.myc construct re-
vealed a band with a molecular weight of 31–33 kD (Fig. 7
B). The predicted size of the recombinant protein is 25.7
kD, thus the difference between the predicted and the ob-
served size (i.e., 6–8 kD) is in agreement with the one
observed among the differently glycosylated products ob-
tained in the in vitro translation experiments. Furthermore,
both the recombinant proteins, Eva.cds and Eva.myc,
were recognized in immunoblotting by a rabbit antiserum
raised against an NH2-terminal peptide of EVA (data not
shown and Fig. 7 C). The same antiserum was tested in
Western blot analysis on SDS lysates of TNC.R3.1 and
A89A cells. Three bands with molecular weights of 32, 30,
and 24 kD, respectively, likely corresponding to different
glycoforms of EVA, were revealed in the TNC.R3.1 sam-
ple and were absent in A89A lysate. The same results
were obtained under nonreducing conditions (data not
shown), implying that EVA is expressed at the cell sur-
face, and is devoid of interchain disulfide bridges.
Cell Separation and Homotypic Adhesiveness of EVA
The poor recovery of EVA in the soluble fraction of Tri-
ton X-100 cell lysates of thymic epithelial cell lines (data
not shown) prompted us to separate cells into soluble and
particulate fractions to determine the solubility of EVA
and assess its association with the cytoskeleton, as it has
been proposed for the Po protein (Wong and Filbin, 1994).
TNC.R3.1 and A89A cells were lysed in hypotonic buffer
and then separated in P1 (containing nuclei and cytoskele-
ton), P100 (membranes), and S100 (soluble proteins) frac-
tions, as detailed in Materials and Methods. Immunoblots
of these fractions with anti-EVA rabbit serum 833 re-
vealed the almost exclusive presence of EVA in the P1
fraction of TNC.R3.1 cells at this exposure time (Fig. 7 D).
Only long exposures of the membrane revealed the pres-
ence of EVA in the P100 fraction, implying that EVA is
predominantly insoluble in hypotonic buffer. The same
membranes were stripped and hybridized with anti-actin
Table I. Expression of Eva Assessed by RT-PCR
Ex vivo Cell line
Tissue
Skin 1 T lymphocyte
Testis 1 M15S 2
Cells Macrophage
CD251 thymocyte 2 MT2 2
B lymphocyte 2 Dendritic
T lymphocyte 2 FSDC 2
Macrophage 2 Fibroblast
Dendritic 2 NIH3T3 2
Bone marrow 2 Bone marrow
Fetal thymus Stroma
(day p.c.) MS-5 2
13.5 1 M210 2
14.5 1 BMS2 2
16.5 1 Multipotent HSC
Fetal liver FDCP mix 2
(day p.c.) Thymus
13.5 1 Epithelium
14.5 1 A89A 2
16.5 1 A2T 2
Embryo TEC 1
(day p.c.) MTE 1
7.5 1 24B6 1
8.5 1 TNC.R3.1 1
9.5 1 Thymocyte
10.5 1 BW5147 2
11.5 1 M15T 2
11.5* 1 M14T 2
Fibroblast
1D4 2
*Extraembryonic tissue.The Journal of Cell Biology, Volume 141, 1998 1068
and anti-Src mouse mAbs. Fig. 7 D shows the presence of
actin in the P1 and S100 fractions, as expected, and of Src
exclusively in the P100 fraction, demonstrating the effec-
tiveness of the lysis and the efficient isolation of cell mem-
branes. The same result was obtained using TEC cells
(data not shown). Whether the insolubility of EVA is due
to formation of large homotypic aggregates (see below) or
to association with cytoskeleton is under investigation.
To evaluate the adhesive properties of EVA-expressing
cells, we performed an aggregation assay in which EVA.
myc.transfected CHO and mock-transfected CHO cells were
labeled with different lipophilic fluorochromes. Single-cell
suspensions were allowed to aggregate and the presence of
cell clusters was monitored by microscopic examination.
As shown in Fig. 8 A, nonrecombinant pcDNA3-trans-
fected CHO cells were scattered as a single-cell suspen-
sion, whereas EVA-expressing CHO cells formed large
cell clusters after 60 min of incubation (Fig. 8 B). Large ag-
gregates (. 10 cells) were observed only in the case of
Eva-transfected cells and the aggregation index appeared
to be fourfold higher than the one observed with parental
cells (Fig. 8 C). Same results were obtained also when the
aggregation assay was performed with unlabeled cells
(data not shown). When monocellular suspensions of the
two cell lines were mixed in a 1:1 ratio, EVA-expressing
cells aggregated on their own (Fig. 8 D) in a 90-min assay,
but not at 30 min, and random incorporation of parental
CHO into aggregates was observed within a range be-
tween 10 and 20% (data not shown). Furthermore, when
the two unlabeled cell lines were mixed at a 1:1 ratio and
stained with FITC-labeled 9E10 anti-myc mAb, the ob-
tained cell clusters were selectively fluorescent, whereas
scattered cells were detected only by phase-contrast analy-
sis (Fig. 8, E and F). These results demonstrate that EVA
expression can mediate cell aggregation, most likely through
an homotypic interaction.
Discussion
Recombinase-deficient mice display a T cell maturation
arrest at an early lymphoid precursor stage (DN CD251
CD442) (Shinkai et al., 1992). Since organogenesis de-
pends on thymocyte–stroma cross-talk, this thymocyte de-
fect also has an impact on the stromal component of the
thymus, which fails to develop a medullary compartment
(Holländer et al., 1995). Moreover, it is clear from various
experimental systems that thymocytes at different matura-
tion stages exert a distinct influence on stromal epithelial
cells (Boyd et al., 1993; Ritter and Boyd, 1993). In RAG-
22/2 mice, massive transition to the thymocyte DP stage
can be induced by in vivo cross-linking of CD3, which is
expressed at low level on the membrane of RAG-22/2 thy-
mocytes (Jacobs et al., 1994; Shinkai and Alt, 1994). This
treatment induces the characteristic phenotypic modifica-
Figure 7.( A ) In vitro trans-
lation of mouse Eva tran-
script. In vitro translation
was performed in the ab-
sence (lanes 1, 3, and 5) or in
the presence (lanes 2, 4, and
6) of canine pancreatic mi-
crosomal membranes. Trans-
lated polypeptides were frac-
tionated through a 12%
SDS-PAGE gel and then an-
alyzed by fluorography.
Lanes  1 and 2: no RNA as
negative control. Lanes 3 and
4:  Saccharomyces cerevisiae
a-factor mRNA, used as pos-
itive control for both transla-
tion and glycosylation. The
a-factor and the core-glyco-
sylated precursor have mo-
lecular weights of 18.6 and 32
kD, respectively. Lanes 5 and
6, Eva mRNA. Lanes 7 and
8: Eva mRNA as in lane 6 or
treated with the enzyme
endo-H. Positions of molecu-
lar mass markers (in kDs)
are indicated on the right.
(B) Cellular localization and immunoblot of chimeric EVA. Left, anti-myc immunofluorescence on CHO cells transfected with either
pcDNA.3 vector (top) or Eva.myc vector (bottom). Right, anti-myc immunoblot on Triton X-100 lysates from the same cells. (C) Anti-
EVA immunoblot. Western analysis with rabbit anti-EVA serum of Triton X-100 lysates from CHO cells transfected with either
pcDNA.3 vector or Eva.myc vector and lysates in SDS of thymic epithelial cell lines A89A and TNC.R3.1. (D) EVA recovery in insolu-
ble cell fraction. TNC.R3.1 and A89A cells were lysed in hypotonic buffer and separated into three fractions: P1, pellet of low-speed
centrifugation; P100, pellet recovered after 100,000 g centrifugation, S100, soluble fraction. Equivalent amounts of all samples were re-
solved by SDS-PAGE in a 5–15% gradient gel and immunoblotted with rabbit anti-EVA antiserum, anti-actin and anti-src mAbs. EVA
is exclusively present in the P1 fraction of TNC.R3.1 cells.Guttinger et al. Regulated Expression and Potential Role of EVA 1069
tions occurring in thymocytes during the physiological
transition (Nikolic-Zugic, 1991) and determines the ex-
pansion of the cortex that becomes histologically indistin-
guishable from the wild-type counterpart (data not shown).
We have exploited the possibility to time a synchronous
T cell maturation event offered by this experimental sys-
tem, with the aim of identifying regulated genes in the
course of thymus development. RNA fingerprinting at dif-
ferent intervals after the injection of anti-CD3e mAb al-
lowed us to isolate a new member of the immunoglobulin
gene superfamily named Eva, whose expression is mark-
edly downregulated at 48 h after the treatment, when thy-
mocytes have completely downregulated the IL-2 receptor
(CD25) and are in the CD4–8lo stage, immediately preced-
ing the acquisition of the DP phenotype. EVA is ex-
pressed in the epithelial component of the organ, thus is
apparently downregulated by a signal, or extinction of a
signal, coming from maturing thymocytes. Considering cy-
tokines as potential inducers of EVA expression in the
thymus epithelium, it is interesting to note that acquisition
of DP phenotype, which constitutes the bulk population in
wild-type thymus, is accompanied by the loss of cytokines’
production (Zlotnik and Moore, 1995). This phenomenon
was also observed in RAG-22/2 mice for IFNg and TNFa
48 h after anti-CD3 injection (our unpublished observa-
tions).
EVA bears a characteristic V-type domain and two po-
tential N-glycosylation sites in the extracellular domain; a
putative serine phosphorylation site for casein kinase 2 is
also present in the cytoplasmic tail; those sites could ac-
count for posttranslational modification of the molecule. It
shows a high degree of homology (45%) with the myelin
Po protein, which is critically involved in compaction of
peripheral nervous system myelin via interactions through
both its extracellular and cytoplasmic domains (Lemke
and Axel, 1985). It has been shown that the immunoglobu-
lin-like domain of Po mediates homophilic interactions of
the molecule (Filbin et al., 1990); moreover, it has been
proposed that the association of the cytoplasmic tail of Po
with the cytoskeleton strengthens the homophilic adhesive
interaction by inducing conformational changes and clus-
tering of the extracellular domain (Wong and Filbin,
1996). The reported homology between Po and EVA
prompted us to investigate functional similarities between
the two molecules. Analogous to that observed with Po,
we could show that EVA is largely insoluble in thymus-
derived epithelial cell lines and that, after transfection of
CHO cells, is able to mediate homophilic cell–cell adhe-
sion.
In the thymus, the importance of epithelial interactions
for appropriate organ histogenesis has been recently un-
derlined by a study describing the absence of thymus organ-
ogenesis in vitro, in a reaggregated organ culture system,
by blocking a homophilic interaction of E-cadherin (Muller
et al., 1997). Various other cell adhesion molecules have
been hypothesized to play a role in thymus morphogenesis
(Patel and Haynes, 1993); the structural and functional
properties of EVA are particularly attractive in this re-
spect, offering a likely new candidate for such a role. The
strong downregulation of Eva expression induced by thy-
mocyte maturation and expansion might suggest a role for
EVA in compaction of the thymic epithelial framework
during early thymus organogenesis, a situation that is ab-
errantly procrastinated in RAG-deficient mice. The EVA-
dependent adhesiveness of epithelium would not be
needed once the thymocyte compartment has sufficiently
Figure 8. EVA-mediated cell
aggregation. Nonrecombi-
nant pcDNA.3-transfected
CHO and Eva.myc-trans-
fected CHO were detached
and labeled, either with
PKH26 or PKH2, respec-
tively. After dissociation, the
two cell lines were allowed to
aggregate in suspension cul-
ture, either alone or mixed in
a 1:1 ratio, and then analyzed
90 min after incubation in
low Ca buffer. Vector-trans-
fected cells are scattered as a
single cell suspension (A),
whereas large cell clusters
are formed by Eva.myc-
expressing cells (B). Extent
of aggregation is expressed
by aggregation index, calcu-
lated as D 5 (N0 - N90)/N0.
Large aggregates (.5 cells)
represented the 8.5% of the
total events in mock-trans-
fected cells and 60% in Eva-myc cells (C). In the coculture, EVA-expressing cells aggregate on their own; random incorporation of pa-
rental CHO into aggregates never exceeded 10–20% (D). Coaggregation experiments with unlabeled cells were done as described
above. Immunofluorescence staining with anti-myc mAb shows selective labeling of cells forming aggregates (E), when compared with
phase-contrast analysis of the same field (F). Bars: (A and B) 50 mm; (D–F) 25 mm. The Journal of Cell Biology, Volume 141, 1998 1070
expanded. Suggestively, in the embryonic thymus, we
could detect the highest level of Eva expression at 14-d
p.c., which can be considered a developmental stage analo-
gous to the one at which RAG-22/2 mice are arrested, im-
mediately preceding the expression of a rearranged TCRb
chain.
At present, we cannot rule out the possibility that EVA
binds through a lectin-like interaction, as hypothesized for
Po (Filbin and Tennekoon, 1991) and/or with an hetero-
philic ligand expressed on thymocyte, as it has been shown
for E-cadherin (Karecla et al., 1995). If this were the case,
EVA downregulation by DP transition would reflect the
need of thymocytes to move to a more appropriate stage-
specific niche in the organ. Accordingly, it has been shown
that the progress of thymocyte maturation renders the
cells less adhesive to stroma (Nishimura et al., 1990).
Finally,  Eva expression in several epithelia suggests
other potential roles for EVA in addition to the putative
ones envisaged during thymus organogenesis. The early
expression of Eva during embryogenesis and its selective
epithelial localizations are particularly significant in this
respect.
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